Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Healthtrust
Harvard Business School
Baxter
Boehringer Ingelheim
Cipla
Citi
Daiichi Sankyo
Chubb
UBS

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090939

« Back to Dashboard

NDA 090939 describes ESCITALOPRAM OXALATE, which is a drug marketed by Mylan Pharms Inc, Amneal Pharms, Antrim Pharms Llc, Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Silarx Pharms Inc, Taro, Accord Hlthcare, Apotex Inc, Hikma Pharms, Invagen Pharms, Jubilant Generics, Lupin Ltd, Prinston Inc, Sti Pharma Llc, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Pharms Usa Inc, and is included in twenty-three NDAs. It is available from fifty-nine suppliers. Additional details are available on the ESCITALOPRAM OXALATE profile page.

The generic ingredient in ESCITALOPRAM OXALATE is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.
Summary for 090939
Tradename:ESCITALOPRAM OXALATE
Applicant:Torrent Pharms Ltd
Ingredient:escitalopram oxalate
Patents:0
Therapeutic Class:Antidepressants
Anxiolytics
Pharmacology for NDA: 090939
Mechanism of ActionSerotonin Uptake Inhibitors
Suppliers and Packaging for NDA: 090939
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ESCITALOPRAM OXALATE escitalopram oxalate TABLET;ORAL 090939 ANDA Major Pharmaceuticals 0904-6426 E 0904-6426-61
ESCITALOPRAM OXALATE escitalopram oxalate TABLET;ORAL 090939 ANDA Major Pharmaceuticals 0904-6427 E 0904-6427-61

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Sep 11, 2012TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Sep 11, 2012TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:Sep 11, 2012TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
McKinsey
Daiichi Sankyo
Medtronic
AstraZeneca
UBS
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot